|
FY 2020
|
Q4 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER2
|
Actual
|
CER
|
|||
Total Revenue
|
26,617
|
9
|
10
|
7,410
|
11
|
10
|
- Product
Sales
|
25,890
|
10
|
11
|
7,011
|
12
|
11
|
- Collaboration
Revenue
|
727
|
(11)
|
(11)
|
399
|
(4)
|
(4)
|
|
|
|
|
|
|
|
Reported3 EPS4
|
$2.44
|
n/m5
|
n/m
|
$0.78
|
n/m
|
n/m
|
Core6 EPS
|
$4.02
|
15
|
18
|
$1.07
|
19
|
24
|
|
FY 2020
|
Q4 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Tagrisso: Product
Sales
|
4,328
|
36
|
36
|
1,157
|
31
|
28
|
Imfinzi: Product
Sales
|
2,042
|
39
|
39
|
555
|
31
|
29
|
Lynparza: Product
Sales
|
1,776
|
48
|
49
|
496
|
42
|
40
|
Lynparza: Collaboration
Revenue
|
460
|
(25)
|
(25)
|
325
|
(7)
|
(7)
|
Calquence: Product
Sales
|
522
|
n/m
|
n/m
|
182
|
n/m
|
n/m
|
Enhertu: Collaboration
Revenue
|
96
|
n/m
|
n/m
|
33
|
n/m
|
n/m
|
|
FY 2020
|
Q4 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Farxiga: Total
Revenue
|
1,964
|
27
|
30
|
587
|
40
|
40
|
Brilinta: Product
Sales
|
1,593
|
1
|
2
|
363
|
(15)
|
(15)
|
Bydureon: Product
Sales
|
448
|
(18)
|
(18)
|
122
|
(12)
|
(12)
|
Lokelma: Product
Sales
|
76
|
n/m
|
n/m
|
28
|
n/m
|
n/m
|
Roxadustat: Collaboration Revenue
|
30
|
n/m
|
n/m
|
11
|
n/m
|
n/m
|
|
FY 2020
|
Q4 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Symbicort: Product
Sales
|
2,721
|
9
|
10
|
680
|
(5)
|
(5)
|
Pulmicort: Product
Sales
|
996
|
(32)
|
(32)
|
368
|
(11)
|
(14)
|
Fasenra: Product
Sales
|
949
|
35
|
34
|
283
|
38
|
35
|
Breztri: Product
Sales
|
28
|
n/m
|
n/m
|
6
|
n/m
|
n/m
|
Regulatory
approvals
|
- Tagrisso -
adjuvant[11] NSCLC[12] (EGFRm[13])
(US)
- Imfinzi -
new Q4W[14] dosing (US,
EU)
- Lynparza -
ovarian cancer (1st line[15], HRD+[16]) (PAOLA-1) (EU,
JP)
- Lynparza -
prostate cancer (2nd line, BRCAm[17]) (EU,
JP)
- Lynparza -
pancreatic cancer (1st line, BRCAm) (JP)
- Enhertu -
gastric cancer (2nd line+, HER2+[18])
(US)
- Enhertu -
breast cancer (3rd line, HER2+) (EU)
- Calquence -
CLL[19] (EU,
JP)
- Forxiga -
HF[20] CVOT[21] (EU,
JP, CN)
- Brilinta -
stroke (THALES) (US)
- Symbicort -
mild asthma (CN)
- Trixeo -
COPD[22] (EU)
- C19VAZ -
COVID-19 (UK; authorisation for emergency supply, EU; conditional
marketing authorisation)
|
Regulatory
submission acceptances and/or submissions
|
- Tagrisso -
adjuvant NSCLC (EGFRm) (EU)
- Lynparza
- prostate cancer (2nd line, BRCAm) (CN)
- Farxiga -
CKD[23] (US, JP;
priority reviews, EU, CN)
-
anifrolumab - lupus (SLE[24])
(JP)
|
Major
Phase III data readouts or other significant
developments
|
- Imfinzi -
biliary tract cancer: Orphan Drug Designation (US)
- Imfinzi +
treme[25] - head &
neck cancer (1st line): Phase III primary endpoint not
met
-
tremelimumab - liver cancer: orphan designation (EU)
- Calquence -
CLL (R/R[26]) (ELEVATE R/R):
Phase III primary endpoint met
-
tezepelumab - severe asthma: Phase III primary endpoint
met
|
Timing
|
News
flow
|
H1 2021
|
- Tagrisso -
adjuvant NSCLC (EGFRm): regulatory decision (CN)
- Imfinzi -
unresectable[27], Stage III NSCLC
(PACIFIC-2): data readout, regulatory submission
- Imfinzi +/-
treme - NSCLC (1st line) (POSEIDON): data readout (OS[28])
- Lynparza -
breast cancer (BRCAm): regulatory decision (CN)
- Lynparza -
adjuvant breast cancer: data readout
- Calquence -
CLL (R/R) (ELEVATE R/R): regulatory submission
- Koselugo -
NF1[29]:
regulatory decision (EU)
- Farxiga -
CKD: regulatory decision (US)
- Brilique/Brilinta -
CAD[30]/T2D[31] CVOT:
regulatory decision (EU, JP, CN)
- Brilique -
stroke (THALES): regulatory decision (EU)
-
roxadustat - anaemia in CKD: regulatory decision (US)
- Symbicort -
mild asthma: regulatory decision (EU)
- Fasenra -
nasal polyps[32]: regulatory
submission
-
tezepelumab - severe asthma: regulatory submission
- C19VAZ -
SARS-CoV-2: data readout, regulatory submission (US)
-
AZD7442 - SARS-CoV-2: data readout, regulatory
submission
|
H2 2021
|
- Tagrisso -
adjuvant NSCLC (EGFRm): regulatory decision (EU)
- Imfinzi -
NSCLC (1st line) (PEARL): data readout, regulatory
submission
- Imfinzi +/-
treme - NSCLC (1st line) (POSEIDON): regulatory
submission
- Imfinzi +/-
treme - liver cancer (1st line): data readout, regulatory
submission
- Lynparza -
adjuvant breast cancer: regulatory submission
- Lynparza
- prostate cancer (2nd line, BRCAm): regulatory
decision (CN)
- Lynparza -
prostate cancer (1st line, castration-resistant): data readout,
regulatory submission
- Enhertu -
breast cancer (3rd line, HER2+) (Phase III): data
readout
- Enhertu -
breast cancer (2nd line, HER2+): data readout, regulatory
submission
- Enhertu -
breast cancer (HER2 low[33]): data
readout
- Forxiga -
CKD: regulatory decision (EU, JP, CN)
- Farxiga -
HF (HFpEF[34]): data
readout
- Brilinta -
stroke (THALES): regulatory decision (CN)
-
PT027 - asthma: data readout
-
anifrolumab - lupus (SLE): regulatory decision (US, EU,
JP)
|
2022
|
- Imfinzi -
ES-SCLC[35]: regulatory
decision (CN)
- Imfinzi -
LS-SCLC[36]: data readout,
regulatory submission
- Imfinzi -
liver cancer (locoregional): data readout, regulatory
submission
- Imfinzi -
biliary tract cancer: data readout, regulatory
submission
- Lynparza -
ovarian cancer (3rd line, BRCAm): regulatory
submission
- Enhertu -
breast cancer (3rd line, HER2+) (Phase III): regulatory
submission
- Enhertu -
breast cancer (HER2 low): regulatory submission
- Calquence -
CLL: regulatory submission (CN)
- Koselugo -
NF1: regulatory submission (JP, CN)
- Farxiga -
HF (HFpEF): regulatory submission
-
roxadustat - MDS[37]: data readout,
regulatory submission
-
PT027 - asthma: regulatory submission
-
nirsevimab - RSV[38]: data
readout
|
|
FY 2020
|
Q4 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Oncology
|
11,455
|
43
|
23
|
24
|
3,270
|
24
|
23
|
BioPharmaceuticals
|
10,077
|
38
|
3
|
4
|
2,786
|
3
|
2
|
- New CVRM
|
4,702
|
18
|
7
|
9
|
1,252
|
7
|
7
|
- Respiratory &
Immunology
|
5,375
|
20
|
(1)
|
-
|
1,534
|
(1)
|
(2)
|
Other
medicines
|
5,085
|
19
|
(4)
|
(2)
|
1,354
|
3
|
2
|
|
|
|
|
|
|
|
|
Total
|
26,617
|
100
|
9
|
10
|
7,410
|
11
|
10
|
Medicine
|
Therapy Area
|
FY 2020
|
Q4 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
||||
Actual
|
CER
|
Actual
|
CER
|
|||||
Tagrisso
|
Oncology
|
4,328
|
16
|
36
|
36
|
1,157
|
31
|
28
|
Symbicort
|
Respiratory & Immunology
|
2,721
|
10
|
9
|
10
|
680
|
(5)
|
(5)
|
Lynparza
|
Oncology
|
2,236
|
8
|
24
|
24
|
821
|
17
|
16
|
Imfinzi
|
Oncology
|
2,042
|
8
|
39
|
39
|
555
|
31
|
29
|
Farxiga
|
CVRM
|
1,964
|
7
|
27
|
30
|
587
|
40
|
40
|
Brilinta
|
CVRM
|
1,593
|
6
|
1
|
2
|
363
|
(15)
|
(16)
|
Nexium
|
Other medicines
|
1,524
|
6
|
1
|
2
|
384
|
7
|
5
|
Crestor
|
CVRM
|
1,182
|
4
|
(10)
|
(9)
|
298
|
(9)
|
(10)
|
Pulmicort
|
Respiratory & Immunology
|
996
|
4
|
(32)
|
(32)
|
368
|
(11)
|
(14)
|
Fasenra
|
Respiratory & Immunology
|
949
|
4
|
35
|
34
|
283
|
38
|
35
|
|
|
|
|
|
|
|
|
|
Total
|
|
19,535
|
73
|
14
|
15
|
5,496
|
13
|
11
|
|
FY 2020
|
Q4 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Lynparza: regulatory milestone
revenue
|
160
|
22
|
n/m
|
n/m
|
25
|
n/m
|
n/m
|
Lynparza: sales milestone
revenue
|
300
|
41
|
(33)
|
(33)
|
300
|
20
|
20
|
Enhertu: share of gross
profits
|
94
|
13
|
n/m
|
n/m
|
31
|
n/m
|
n/m
|
Roxadustat: share of gross profits
|
30
|
4
|
n/m
|
n/m
|
11
|
n/m
|
n/m
|
Other Ongoing Collaboration Revenue
|
143
|
20
|
(32)
|
(32)
|
32
|
(53)
|
(54)
|
|
|
|
|
|
|
|
|
Total
|
727
|
100
|
(11)
|
(11)
|
399
|
(4)
|
(4)
|
Product Sales:
therapy area
|
Medicine
|
FY 2020
|
|||
$m
|
% of total Product Sales
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
4,328
|
17
|
36
|
36
|
Imfinzi
|
2,042
|
8
|
39
|
39
|
|
Lynparza
|
1,776
|
7
|
48
|
49
|
|
Calquence
|
522
|
2
|
n/m
|
n/m
|
|
Koselugo
|
38
|
-
|
n/m
|
n/m
|
|
Zoladex[41]
|
888
|
3
|
9
|
13
|
|
Faslodex41
|
580
|
2
|
(35)
|
(34)
|
|
Iressa41
|
268
|
1
|
(37)
|
(36)
|
|
Arimidex41
|
185
|
1
|
(18)
|
(16)
|
|
Casodex41
|
172
|
1
|
(14)
|
(14)
|
|
Others
|
51
|
-
|
(47)
|
(46)
|
|
Total Oncology
|
10,850
|
42
|
25
|
26
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
1,959
|
8
|
27
|
30
|
Brilinta
|
1,593
|
6
|
1
|
2
|
|
Onglyza
|
470
|
2
|
(11)
|
(10)
|
|
Bydureon
|
448
|
2
|
(18)
|
(18)
|
|
Byetta
|
68
|
-
|
(37)
|
(36)
|
|
Other diabetes
|
47
|
-
|
(10)
|
(10)
|
|
Lokelma
|
76
|
-
|
n/m
|
n/m
|
|
Crestor41
|
1,180
|
5
|
(8)
|
(7)
|
|
Seloken/Toprol-XL41
|
821
|
3
|
8
|
12
|
|
Atacand41
|
243
|
1
|
10
|
15
|
|
Others
|
191
|
1
|
(30)
|
(30)
|
|
BioPharmaceuticals:
total CVRM
|
7,096
|
27
|
3
|
5
|
|
BioPharmaceuticals: Respiratory & Immunology
|
Symbicort
|
2,721
|
11
|
9
|
10
|
Pulmicort
|
996
|
4
|
(32)
|
(32)
|
|
Fasenra
|
949
|
4
|
35
|
34
|
|
Daliresp/Daxas
|
217
|
1
|
1
|
1
|
|
Bevespi
|
48
|
-
|
16
|
15
|
|
Breztri
|
28
|
-
|
n/m
|
n/m
|
|
Others
|
398
|
2
|
(15)
|
(15)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
5,357
|
21
|
(1)
|
-
|
|
Other medicines
|
Nexium41
|
1,492
|
6
|
1
|
2
|
Synagis41
|
372
|
1
|
4
|
4
|
|
FluMist41
|
295
|
1
|
n/m
|
n/m
|
|
Losec/Prilosec41
|
183
|
1
|
(30)
|
(30)
|
|
Seroquel XR/IR41
|
117
|
-
|
(39)
|
(37)
|
|
Others
|
128
|
-
|
(33)
|
(34)
|
|
Total other medicines
|
2,587
|
10
|
(1)
|
-
|
|
|
Total Product Sales
|
25,890
|
100
|
10
|
11
|
Total Collaboration Revenue
|
727
|
|
(11)
|
(11)
|
|
Total Revenue
|
26,617
|
|
9
|
10
|
Product Sales:
therapy area
|
Medicine
|
Q4 2020
|
|||
$m
|
% of total Product Sales
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
1,157
|
17
|
31
|
28
|
Imfinzi
|
555
|
8
|
31
|
29
|
|
Lynparza
|
496
|
7
|
42
|
40
|
|
Calquence
|
182
|
3
|
n/m
|
n/m
|
|
Koselugo
|
17
|
-
|
n/m
|
n/m
|
|
Zoladex
|
216
|
3
|
11
|
13
|
|
Faslodex
|
130
|
2
|
(21)
|
(22)
|
|
Iressa
|
67
|
1
|
(16)
|
(19)
|
|
Arimidex
|
36
|
1
|
(29)
|
(30)
|
|
Casodex
|
39
|
1
|
(10)
|
(13)
|
|
Others
|
13
|
-
|
(53)
|
(52)
|
|
Total Oncology
|
2,908
|
41
|
28
|
26
|
|
BioPharmaceuticals: CVRM
|
Farxiga
|
586
|
8
|
40
|
40
|
Brilinta
|
363
|
5
|
(15)
|
(15)
|
|
Onglyza
|
105
|
1
|
(20)
|
(21)
|
|
Bydureon
|
122
|
2
|
(12)
|
(12)
|
|
Byetta
|
19
|
-
|
(31)
|
(30)
|
|
Other diabetes
|
12
|
-
|
(23)
|
(22)
|
|
Lokelma
|
28
|
-
|
n/m
|
n/m
|
|
Crestor
|
298
|
4
|
1
|
(1)
|
|
Seloken/Toprol-XL
|
200
|
3
|
6
|
7
|
|
Atacand
|
63
|
1
|
5
|
9
|
|
Others
|
46
|
1
|
(38)
|
(40)
|
|
BioPharmaceuticals:
total CVRM
|
1,842
|
26
|
3
|
3
|
|
BioPharmaceuticals: Respiratory & Immunology
|
Symbicort
|
680
|
10
|
(5)
|
(5)
|
Pulmicort
|
368
|
5
|
(11)
|
(14)
|
|
Fasenra
|
283
|
4
|
38
|
35
|
|
Daliresp/Daxas
|
54
|
1
|
(6)
|
(7)
|
|
Bevespi
|
12
|
-
|
8
|
4
|
|
Breztri
|
6
|
-
|
n/m
|
n/m
|
|
Others
|
125
|
2
|
(8)
|
(12)
|
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,528
|
22
|
(1)
|
(2)
|
|
Other medicines
|
Nexium
|
377
|
5
|
7
|
6
|
Synagis
|
78
|
1
|
24
|
24
|
|
FluMist
|
179
|
3
|
92
|
85
|
|
Losec/Prilosec
|
39
|
1
|
(15)
|
(18)
|
|
Seroquel XR/IR
|
19
|
-
|
(53)
|
(49)
|
|
Others
|
41
|
1
|
(30)
|
(31)
|
|
Total other medicines
|
733
|
10
|
12
|
10
|
|
|
Total Product Sales
|
7,011
|
100
|
12
|
11
|
Total Collaboration Revenue
|
399
|
|
(4)
|
(4)
|
|
Total Revenue
|
7,410
|
|
11
|
10
|
|
FY 2020
|
Q4 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Emerging
Markets
|
8,711
|
33
|
7
|
10
|
2,244
|
7
|
8
|
- China
|
5,375
|
20
|
10
|
11
|
1,362
|
15
|
9
|
- Ex-China
|
3,336
|
13
|
1
|
9
|
882
|
(2)
|
7
|
|
|
|
|
|
|
|
|
US
|
8,833
|
33
|
13
|
13
|
2,388
|
15
|
15
|
|
|
|
|
|
|
|
|
Europe
|
5,540
|
21
|
10
|
9
|
1,831
|
17
|
12
|
|
|
|
|
|
|
|
|
Established
RoW
|
3,533
|
13
|
6
|
5
|
947
|
2
|
(1)
|
- Japan
|
2,620
|
10
|
1
|
-
|
718
|
(2)
|
(5)
|
- Canada
|
605
|
2
|
29
|
31
|
146
|
16
|
16
|
- Other
Est. RoW
|
308
|
1
|
8
|
10
|
83
|
11
|
7
|
|
|
|
|
|
|
|
|
Total
|
26,617
|
100
|
9
|
10
|
7,410
|
11
|
10
|
|
FY 2020
|
Q4 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Oncology
|
2,906
|
33
|
31
|
36
|
668
|
22
|
24
|
BioPharmaceuticals
|
3,007
|
35
|
(4)
|
-
|
882
|
2
|
2
|
- New CVRM
|
1,407
|
16
|
24
|
31
|
335
|
12
|
17
|
- Respiratory &
Immunology
|
1,600
|
18
|
(19)
|
(18)
|
547
|
(4)
|
(5)
|
Other medicines
|
2,798
|
32
|
(1)
|
2
|
694
|
2
|
3
|
|
|
|
|
|
|
|
|
Total
|
8,711
|
100
|
7
|
10
|
2,244
|
7
|
8
|
|
FY 2020
|
Q4 2020
|
|||||
$m
|
% of total
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
||||
Tagrisso
|
1,208
|
14
|
59
|
63
|
258
|
23
|
23
|
Forxiga
|
686
|
8
|
46
|
55
|
198
|
50
|
57
|
Brilinta
|
461
|
5
|
-
|
4
|
69
|
(40)
|
(37)
|
Lynparza[45]
|
264
|
3
|
98
|
n/m
|
69
|
n/m
|
n/m
|
|
FY 2020
|
Q4 2020
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Ex-China Asia Pacific
|
1,237
|
5
|
6
|
341
|
7
|
5
|
Middle East and Africa
|
1,024
|
(3)
|
1
|
256
|
(12)
|
(5)
|
Ex-Brazil Latin America
|
447
|
-
|
18
|
130
|
2
|
21
|
Russia
|
314
|
28
|
42
|
77
|
11
|
33
|
Brazil
|
314
|
(15)
|
10
|
78
|
(17)
|
11
|
|
|
|
|
|
|
|
Total
|
3,336
|
1
|
9
|
882
|
(2)
|
7
|
|
FY 2020
|
FY 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
26,617
|
24,384
|
9
|
10
|
- Product
Sales
|
25,890
|
23,565
|
10
|
11
|
- Collaboration
Revenue
|
727
|
819
|
(11)
|
(11)
|
|
|
|
|
|
Cost of Sales
|
(5,299)
|
(4,921)
|
8
|
8
|
|
|
|
|
|
Gross Profit
|
21,318
|
19,463
|
10
|
11
|
Gross Profit Margin
|
79.5%
|
79.1%
|
-
|
+1
|
|
|
|
|
|
Distribution Expense
|
(399)
|
(339)
|
18
|
19
|
% Total Revenue
|
1.5%
|
1.4%
|
-
|
-
|
R&D Expense
|
(5,991)
|
(6,059)
|
(1)
|
(1)
|
% Total Revenue
|
22.5%
|
24.8%
|
+2
|
+3
|
SG&A Expense
|
(11,294)
|
(11,682)
|
(3)
|
(3)
|
% Total Revenue
|
42.4%
|
47.9%
|
+5
|
+6
|
|
|
|
|
|
Other Operating Income & Expense
|
1,528
|
1,541
|
(1)
|
(1)
|
% Total Revenue
|
5.7%
|
6.3%
|
-1
|
-1
|
|
|
|
|
|
Operating Profit
|
5,162
|
2,924
|
77
|
81
|
Operating Profit Margin
|
19.4%
|
12.0%
|
+7
|
+8
|
|
|
|
|
|
Net Finance Expense
|
(1,219)
|
(1,260)
|
(3)
|
(4)
|
Joint Ventures and Associates
|
(27)
|
(116)
|
(77)
|
(76)
|
|
|
|
|
|
Profit Before Tax
|
3,916
|
1,548
|
n/m
|
n/m
|
|
|
|
|
|
Taxation
|
(772)
|
(321)
|
n/m
|
n/m
|
Tax Rate
|
20%
|
21%
|
|
|
|
|
|
|
|
Profit After Tax
|
3,144
|
1,227
|
n/m
|
n/m
|
|
|
|
|
|
EPS
|
$2.44
|
$1.03
|
n/m
|
n/m
|
|
Q4 2020
|
Q4 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Total Revenue
|
7,410
|
6,664
|
11
|
10
|
- Product
Sales
|
7,011
|
6,250
|
12
|
11
|
- Collaboration
Revenue
|
399
|
414
|
(4)
|
(4)
|
|
|
|
|
|
Cost of Sales
|
(1,525)
|
(1,378)
|
11
|
5
|
|
|
|
|
|
Gross Profit
|
5,885
|
5,286
|
11
|
11
|
Gross Profit Margin
|
78.2%
|
78.0%
|
-
|
+1
|
|
|
|
|
|
Distribution Expense
|
(109)
|
(92)
|
18
|
16
|
% Total Revenue
|
1.5%
|
1.4%
|
-
|
-
|
R&D Expense
|
(1,719)
|
(2,091)
|
(18)
|
(19)
|
% Total Revenue
|
23.2%
|
31.4%
|
+8
|
+8
|
SG&A Expense
|
(3,210)
|
(3,026)
|
6
|
4
|
% Total Revenue
|
43.3%
|
45.4%
|
+2
|
+2
|
|
|
|
|
|
Other Operating Income & Expense
|
640
|
500
|
28
|
29
|
% Total Revenue
|
8.6%
|
7.5%
|
+1
|
+1
|
|
|
|
|
|
Operating Profit
|
1,487
|
577
|
n/m
|
n/m
|
Operating Profit Margin
|
20.1%
|
8.7%
|
+11
|
+13
|
|
|
|
|
|
Net Finance Expense
|
(314)
|
(312)
|
1
|
-
|
Joint Ventures and Associates
|
(6)
|
(25)
|
(79)
|
(79)
|
|
|
|
|
|
Profit Before Tax
|
1,167
|
240
|
n/m
|
n/m
|
|
|
|
|
|
Taxation
|
(162)
|
37
|
n/m
|
n/m
|
Tax Rate
|
14%
|
(15)%
|
|
|
|
|
|
|
|
Profit After Tax
|
1,005
|
277
|
n/m
|
n/m
|
|
|
|
|
|
EPS
|
$0.78
|
$0.24
|
n/m
|
n/m
|
|
FY 2020
|
FY 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit Before Tax
|
3,916
|
1,548
|
n/m
|
n/m
|
|
|
|
|
|
Net Finance Expense
|
1,219
|
1,260
|
(3)
|
(4)
|
Joint Ventures and Associates
|
27
|
116
|
(77)
|
(76)
|
Depreciation, Amortisation and Impairment
|
3,149
|
3,762
|
(16)
|
(16)
|
|
|
|
|
|
EBITDA
|
8,311
|
6,686
|
24
|
27
|
|
Q4 2020
|
Q4 2019
|
% change
|
|
$m
|
$m
|
Actual
|
CER
|
|
Reported Profit Before Tax
|
1,167
|
240
|
n/m
|
n/m
|
|
|
|
|
|
Net Finance Expense
|
314
|
312
|
1
|
-
|
Joint Ventures and Associates
|
6
|
25
|
(79)
|
(79)
|
Depreciation, Amortisation and Impairment
|
797
|
1,643
|
(52)
|
(53)
|
|
|
|
|
|
EBITDA
|
2,284
|
2,220
|
3
|
6
|
FY 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core[46]
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
21,318
|
53
|
66
|
-
|
5
|
21,442
|
9
|
10
|
Gross Profit Margin
|
79.5%
|
|
|
|
|
80.0%
|
-
|
-
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(399)
|
-
|
-
|
-
|
-
|
(399)
|
18
|
19
|
R&D Expense
|
(5,991)
|
35
|
84
|
-
|
-
|
(5,872)
|
10
|
10
|
SG&A Expense
|
(11,294)
|
162
|
1,657
|
310
|
(197)
|
(9,362)
|
3
|
4
|
Total Operating Expense
|
(17,684)
|
197
|
1,741
|
310
|
(197)
|
(15,633)
|
6
|
6
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
1,528
|
1
|
2
|
-
|
-
|
1,531
|
(2)
|
(2)
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
5,162
|
251
|
1,809
|
310
|
(192)
|
7,340
|
14
|
17
|
Operating Profit Margin
|
19.4%
|
|
|
|
|
27.6%
|
+1
|
+2
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(1,219)
|
-
|
-
|
228
|
209
|
(782)
|
2
|
2
|
Taxation
|
(772)
|
(50)
|
(376)
|
(127)
|
13
|
(1,312)
|
18
|
21
|
|
|
|
|
|
|
|
|
|
EPS
|
$2.44
|
$0.15
|
$1.10
|
$0.31
|
$0.02
|
$4.02
|
15
|
18
|
Q4 2020
|
Reported
|
Restructuring
|
Intangible Asset Amortisation & Impairments
|
Diabetes Alliance
|
Other
|
Core46
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross Profit
|
5,885
|
9
|
16
|
-
|
1
|
5,911
|
12
|
12
|
Gross Profit Margin
|
78.2%
|
|
|
|
|
78.6%
|
+1
|
+2
|
|
|
|
|
|
|
|
|
|
Distribution Expense
|
(109)
|
-
|
-
|
-
|
-
|
(109)
|
18
|
16
|
R&D Expense
|
(1,719)
|
5
|
7
|
-
|
-
|
(1,707)
|
14
|
12
|
SG&A Expense
|
(3,210)
|
95
|
429
|
64
|
(216)
|
(2,838)
|
8
|
6
|
Total Operating Expense
|
(5,038)
|
100
|
436
|
64
|
(216)
|
(4,654)
|
11
|
8
|
|
|
|
|
|
|
|
|
|
Other Operating Income & Expense
|
640
|
2
|
-
|
-
|
-
|
642
|
28
|
29
|
|
|
|
|
|
|
|
|
|
Operating Profit
|
1,487
|
111
|
452
|
64
|
(215)
|
1,899
|
23
|
28
|
Operating Profit Margin
|
20.1%
|
|
|
|
|
25.6%
|
+2
|
+4
|
|
|
|
|
|
|
|
|
|
Net Finance Expense
|
(314)
|
-
|
-
|
54
|
55
|
(205)
|
10
|
15
|
Taxation
|
(162)
|
(22)
|
(92)
|
(35)
|
14
|
(297)
|
52
|
59
|
|
|
|
|
|
|
|
|
|
EPS
|
$0.78
|
$0.06
|
$0.28
|
$0.06
|
($0.11)
|
$1.07
|
19
|
24
|
|
FY 2020
|
FY 2019
|
Change
|
$m
|
$m
|
$m
|
|
Reported Operating Profit
|
5,162
|
2,924
|
2,238
|
Depreciation, Amortisation and Impairment
|
3,149
|
3,762
|
(613)
|
|
|
|
|
Decrease/(increase) in Working Capital and Short-Term
Provisions
|
361
|
(346)
|
707
|
Gains on Disposal of Intangible Assets
|
(1,030)
|
(1,243)
|
213
|
Non-Cash and Other Movements
|
(548)
|
(236)
|
(312)
|
Interest Paid
|
(733)
|
(774)
|
41
|
Taxation Paid
|
(1,562)
|
(1,118)
|
(444)
|
|
|
|
|
Net Cash Inflow from Operating Activities
|
4,799
|
2,969
|
1,830
|
|
|
|
|
Net Cash Inflow before Financing Activities
|
4,514
|
2,312
|
2,202
|
|
|
|
|
Net Cash Outflow from Financing Activities
|
(2,203)
|
(1,765)
|
(438)
|
|
At 31 Dec 2020
|
At 31 Dec 2019
|
$m
|
$m
|
|
Cash
and cash equivalents
|
7,832
|
5,369
|
Other
investments
|
160
|
911
|
|
|
|
Cash and investments
|
7,992
|
6,280
|
|
|
|
Overdrafts
and short-term borrowings
|
(658)
|
(225)
|
Lease
liabilities
|
(681)
|
(675)
|
Current
instalments of loans
|
(1,536)
|
(1,597)
|
Non-current
instalments of loans
|
(17,505)
|
(15,730)
|
|
|
|
Interest-bearing loans and borrowings
(Gross Debt)
|
(20,380)
|
(18,227)
|
|
|
|
Net
derivatives
|
278
|
43
|
Net Debt
|
(12,110)
|
(11,904)
|
|
Average Exchange
Rates versus USD
|
|
Annual Impact of 5% Strengthening in Exchange Rate versus USD
($m)[48]
|
|||
Currency
|
Primary Relevance
|
FY 2020[49]
|
YTD 2021[50]
|
% change
|
Product Sales
|
Core Operating Profit
|
CNY
|
Product
Sales
|
6.90
|
6.47
|
6
|
312
|
186
|
EUR
|
Product
Sales
|
0.88
|
0.82
|
6
|
189
|
58
|
JPY
|
Product
Sales
|
106.74
|
103.70
|
3
|
140
|
91
|
Other[51]
|
|
|
|
|
239
|
108
|
|
|
|
|
|
|
|
GBP
|
Operating
Expense
|
0.78
|
0.73
|
6
|
31
|
(84)
|
SEK
|
Operating
Expense
|
9.20
|
8.29
|
10
|
5
|
(59)
|
New
molecular entities and major lifecycle events for medicines in
Phase III trials or under regulatory review
|
22
|
Oncology
- Tagrisso -
NSCLC
- Imfinzi -
multiple cancers
- Lynparza -
multiple cancers
- Enhertu -
multiple cancers
- Calquence -
blood cancers
-
tremelimumab - multiple cancers
-
savolitinib - NSCLC[53]
-
capivasertib - breast, prostate cancer
-
monalizumab - head & neck cancer
-
camizestrant (AZD9833) - breast cancer
-
datopotamab deruxtecan - lung cancer
CVRM
- Farxiga -
multiple indications
-
roxadustat - anaemia in CKD
Respiratory & Immunology
- Fasenra -
multiple indications
- Breztri -
asthma
-
tezepelumab - severe asthma
-
PT027 - asthma
-
anifrolumab - lupus (SLE)
-
brazikumab - inflammatory bowel disease
-
nirsevimab - RSV
COVID-19
- C19VAZ -
SARS-CoV-2
-
AZD7442 - SARS-CoV-2
|
Total
projects
in
clinical development
|
145
|
|
Total
projects
in
total pipeline
|
171
|
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
NeoADAURA
|
Neo-adjuvant
EGFRm
NSCLC
|
Placebo
or
Tagrisso
|
FPCD[54]
Q1
2021
First
data anticipated
2022+
|
Recruitment
ongoing
|
ADAURA
|
Adjuvant
EGFRm NSCLC
|
Placebo
or Tagrisso
|
FPCD
Q4
2015
LPCD[55]
Q1
2019
|
Trial
unblinded early due to overwhelming efficacy
Regulatory
approval (US)
|
LAURA
|
Locally
advanced, unresectable EGFRm NSCLC
|
Placebo
or
Tagrisso
|
FPCD
Q4
2018
First
data anticipated
2022+
|
Recruitment
ongoing
|
FLAURA2
|
1st-line
EGFRm NSCLC
|
Tagrisso or
Tagrisso + platinum-based chemotherapy
doublet
|
FPCD
Q4
2019
First
data anticipated
2022+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
AEGEAN
|
Neo-adjuvant
NSCLC
|
SoC[57] chemotherapy
+/- Imfinzi,
followed
by
surgery,
followed by placebo
or Imfinzi
|
FPCD
Q1
2019
First
data anticipated
2022+
|
Recruitment
ongoing
|
ADJUVANT
BR.31[58]
|
Stage
Ib-IIIa resected NSCLC
|
Placebo
or
Imfinzi
|
FPCD
Q1
2015
LPCD
Q1
2020
First
data anticipated
2022+
|
Recruitment
completed
|
MERMAID-1
|
Stage
II-III
resected
NSCLC
|
SoC
chemotherapy +/- Imfinzi
|
FPCDQ3
2020
First
data anticipated
2022+
|
Recruitmentongoing
|
MERMAID-2
|
Stage
II-III
NSCLC
with minimal residual disease
|
Placebo
or
Imfinzi
|
FPCDQ4
2020First data anticipated2022+
|
Recruitment
ongoing
|
PACIFIC-2
|
Stage
III unresectable locally advanced NSCLC
(concurrent
CRT)
|
Placebo
or
Imfinzi
|
FPCD
Q2
2018
LPCD
Q3
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
ADRIATIC
|
LS-SCLC
|
Concurrent
CRT,
followed
by
placebo
or
Imfinzi or
Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2022
|
Recruitment
ongoing
|
PEARL
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or Imfinzi
|
FPCD
Q1
2017
LPCD
Q1
2019
First
data anticipated
2022
|
Recruitment
completed
|
POSEIDON
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q2
2017
LPCD
Q4
2018
OS data
anticipated
H1
2021
|
PFS[59] primary
endpoint met
|
CASPIAN
|
ES-SCLC
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q1
2017
LPCD
Q2
2018
|
OS
primary endpoint met for Imfinzi
OS
primary endpoint not met for Imfinzi + treme
Regulatory
approval
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
POTOMAC
|
Non-muscle
invasive bladder cancer
|
SoC
BCG[60] or SoC BCG
+ Imfinzi
|
FPCD
Q4
2018LPCDQ3 2020
First
data
anticipated
2022+
|
Recruitmentcompleted
|
NIAGARA
|
Muscle-invasive
bladder cancer
|
Neo-adjuvant
cisplatin and gemcitabine SoC chemotherapy or SoC
+ Imfinzi, followed by
adjuvant placebo or Imfinzi
|
FPCD
Q4
2018
First
data
anticipated
2022+
|
Recruitment
ongoing
|
EMERALD-1
|
Locoregional
HCC[61]
|
TACE[62] followed
by placebo or
TACE
+ Imfinzi, followed
by Imfinzi +
bevacizumab or
TACE
+ Imfinzi
followed
by Imfinzi
|
FPCD
Q1
2019
First
data
anticipated
2022
|
Recruitment
ongoing
|
EMERALD-2
|
Locoregional
HCC at high risk of recurrence after surgery or radiofrequency
ablation
|
Adjuvant Imfinzi or Imfinzi +
bevacizumab
|
FPCD
Q2
2019
First
data anticipated
2022+
|
Recruitment
ongoing
|
CALLA
|
Locally
advanced cervical cancer
|
CRT or
CRT + Imfinzi,
followed by placebo or Imfinzi
|
FPCD
Q1
2019
LPCDQ4
2020
First
data anticipated
2022+
|
Recruitment
completed
|
MATTERHORN
|
Resectable
gastric and gastroesophageal cancer
|
Neoadjuvant Imfinzi +
FLOT chemotherapy +/- adjuvant Imfinzi
|
FPCDQ4
2020First data anticipated2022+
|
Recruitment
ongoing
|
KUNLUN
|
Locally
advanced, unresectable oesophageal squamous cell
carcinoma
|
Definitive
CRT or CRT + Imfinzi
|
FPCDQ4
2020First data anticipated2022+
|
Recruitmentongoing
|
NILE
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible bladder
cancer
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated
2022+
|
Recruitment
ongoing
|
KESTREL
|
Stage
IV, 1st-line HNSCC[63]
|
SoC
or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
|
Primary
endpoint not met
|
HIMALAYA
|
Stage
IV, 1st-line unresectable HCC
|
Sorafenib
or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2017
LPCD
Q4
2019
First
data
anticipated
H2
2021
|
Recruitment
completed
Orphan
Drug Designation[64] (US)
|
TOPAZ-1
|
Stage
IV, 1st-line biliary-tract cancer
|
Gemcitabine
and cisplatin SoC chemotherapy or SoC + Imfinzi
|
FPCD
Q2
2019
First
data anticipated
2022
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
OlympiA
|
Adjuvant
BRCAm breast cancer
|
SoC
placebo or Lynparza
|
FPCD
Q2
2014
LPCD
Q2
2019
First
data anticipated
H1
2021
|
Recruitment
completed
|
PROfound
|
Metastatic
castration-resistant 2nd-line+ HRRm
prostate
cancer
|
SoC
(abiraterone or enzalutamide) or Lynparza
|
FPCD
Q2
2017
LPCD
Q4
2018
|
Primary
endpoint met
Regulatory
approval
|
PAOLA-1[65]
|
Advanced
1st-line
ovarian
cancer
|
Bevacizumab
maintenance or
bevacizumab
+
Lynparza maintenance
|
FPCD
Q2
2015
LPCD
Q2
2018
|
Primary
endpoint met
Regulatory
approval
|
DuO-O
|
Advanced
1st-line
ovarian
cancer
|
Chemotherapy
+
bevacizumab
or
chemotherapy
+
bevacizumab
+
Imfinzi +/-
Lynparza maintenance
|
FPCD
Q1 2019
First
data
anticipated
2022+
|
Recruitment
ongoing
|
DuO-E
|
Advanced
1st-line
endometrial
cancer
|
Chemotherapy
or
chemotherapy
+
Imfinzi + Imfinzi maintenance
or
chemotherapy
+
Imfinzi followed by Imfinzi + Lynparza maintenance
|
FPCD
Q2 2020
First
data
anticipated
2022+
|
Recruitment
ongoing
|
PROpel
|
Stage
IV, advanced, castration-resistant prostate cancer
|
Abiraterone
or
abiraterone
+
Lynparza
|
FPCD
Q4
2018
First
data
anticipated
H2
2021
|
Recruitment
ongoing
|
LYNK-003
|
Stage
IV, 1st-line colorectal cancer
|
Bevacizumab
+ 5-FU[66] maintenance
or bevacizumab + Lynparza maintenance
or Lynparza maintenance
|
First
data
anticipated
2022+
|
Initiating
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
DESTINY-Breast01-U201
Phase
II
|
Stage
IV, HER2+[67] breast
cancer post trastuzumab emtansine
|
Enhertu
|
FPCD
Q4
2017
LPCD
Q4
2018
|
Primary
objective met
Breakthrough
Therapy Designation[68] (US)
Regulatory
approval (US, EU, JP)
|
DESTINY-Breast02-U301
Phase
III
|
Stage
IV, HER2+ breast cancer post trastuzumab emtansine
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
LPCDQ4
2020
First
data anticipated
H2
2021
|
Recruitment completed
|
DESTINY-Breast03-U302
Phase
III
|
Stage
IV, HER2+ breast cancer
|
Trastuzumab
emtansine or Enhertu
|
FPCD
Q4
2018LPCDQ2 2020
First
data anticipated
H2
2021
|
Recruitment completed
|
DESTINY-Breast04
Phase
III
|
Stage
IV, HER2-low breast cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2018
LPCDQ4
2020
First
data anticipated
H2
2021
|
Recruitment completed
|
DESTINY-Breast06
Phase
III
|
Stage
IV, HER2-low breast cancer post endocrine therapy
|
SoC
chemotherapy or Enhertu
|
FPCDQ3
2020
First
data
anticipated
2022+
|
Recruitment
ongoing
|
DESTINY-Gastric01
Phase
II
|
Stage
IV, HER2+ gastric cancer
|
SoC
chemotherapy or Enhertu
|
FPCD
Q4
2017
LPCD
Q2
2019
|
Primary
endpoint met
Breakthrough
Therapy Designation
(US)
Regulatory
approval (US, JP)
|
DESTINY-PanTumour02
Phase
II
|
HER2-expressing
tumours
|
Enhertu
|
FPCD
Q3
2020First data
anticipated
2022+
|
Recruitment
ongoing
|
DESTINY-
PanTumour01
Phase
II
|
HER2m
tumours
|
Enhertu
|
FPCDQ1
2021First data
anticipated
2022+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
TROPION-LUNG01
Phase
III
|
Stage
IV, NSCLC
|
SoC
chemotherapy or datopotamab deruxtecan
|
First
data anticipated
2022+
|
Initiating
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
Farxiga
|
|
||||
DAPA-HF
|
c.4,500
patients with HFrEF, with and without T2D
|
SoC +
placebo or SoC + Farxiga 10mg or 5mg QD[69]
|
Time to
first occurrence of CV death or hospitalisation due to HF
or
an
urgent HF visit
|
FPCD
Q1
2017
LPCD
Q4
2018
|
Primary
endpoint met
Regulatory
approval
|
DELIVER
|
c.4,700
patients with HF (HFpEF) with and without T2D
|
Placebo
or Farxiga 10mg
QD
|
Time to
first occurrence of CV death or worsening HF
|
FPCD
Q4
2018
First
data anticipatedH2 2021
|
Recruitment
ongoing
Fast
Track[70] designation
(US)
|
DAPA-CKD
|
c.4,000
patients with CKD, with and without T2D
|
Placebo
or Farxiga 10mg
or 5mg QD
|
Time to
first occurrence of ≥ 50% sustained decline in eGFR or
reaching ESRD or CV death or renal death
|
FPCD
Q1
2017
LPCD
Q1
2020
|
Trial
stopped early based on recommendation from an IDMC[71]
Primary
endpoint and secondary endpoints met
Fast
Track designation (US)
|
DAPA-MI
|
c.6,400
patients with confirmed MI, either STEMI or NSTEMI, within the
preceding 7 days
|
Placebo
or Farxiga 10mg
QD
|
Time to
the first occurrence of any of the components of this composite:
hospitalisation for HF or CV death
|
FPCD
Q4
2020First data anticipated2022+
|
Recruitment
ongoing
|
Brilinta
|
|
||||
THEMIS
|
c.19,000
patients with T2D and CAD without a history of MI or
stroke
|
Aspirin
plus placebo or aspirin plus Brilinta 60mg BID[72]
|
Composite
of CV death, non-fatal MI and non-fatal stroke
|
FPCD
Q1
2014
LPCD
Q2
2016
|
Primary
endpoint met
Regulatory
approval (US)
|
THALES
|
c.11,000
patients with acute ischaemic stroke[73] or transient
ischaemic attack
|
Aspirin
plus placebo or aspirin plus Brilinta 90mg BID
|
Prevention
of the composite of subsequent stroke and death at 30
days
|
FPCD
Q1
2018
LPCD
Q4
2019
|
Primary
endpoint met
Regulatory
approval (US)
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
OSTRO
|
Patients
aged 18-75 years with severe bilateral nasal polyps; symptomatic,
despite SoC
|
Placebo
or Fasenra 30mg
Q8W[74] SC[75]
|
Nasal-polyps
burden and reported nasal blockage
|
FPCD
Q1
2018
LPCD
Q2
2019
|
Co-primary
endpoints met
|
RESOLUTE
|
Patients
with moderate to very severe COPD with a history of frequent COPD
exacerbations and elevated peripheral blood
eosinophils
|
Placebo
or Fasenra 100mg
Q8W SC
|
Annualised
rate of moderate or severe COPD exacerbations
|
FPCD
Q4
2019
Data
anticipated 2022+
|
Recruitment
ongoing
|
MANDARA
|
Eosinophilic
granulomatosis with polyangiitis[76]
|
Mepolizumab
3x100mg Q4W or Fasenra 30mg
|
Proportion
of patients who achieve remission, defined as a score[77] =0 and an
OCS dose ≤4 mg/day at weeks 36 and 48
|
FPCD
Q4
2019
Data
anticipated
2022+
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
NATRON
|
HES[78]
|
Placebo
or Fasenra 30mg
Q4W SC
|
Time to
HES worsening flare or any cytotoxic and/or immuno-suppressive
therapy increase or hospitalisation
|
FPCD
Q3
2020
Data
anticipated 2022
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
MESSINA
|
Eosinophilic
oesophagitis[79]
|
Placebo
or Fasenra 30mg
Q4W SC
|
Proportion
of patients with a histologic response[80]
Changes
from baseline in dysphagia[81] PRO[82]
|
FPCD
Q4
2020
Data
anticipated 2022
|
Recruitment
ongoing
Orphan
Drug Designation (US)
|
FJORD
|
BP[83]
|
Placebo
or Fasenra 30mg
Q4W SC
|
Proportion
of patients with partial or
complete
remission of BP whilst off OCS for ≥2 months
at Week
36
|
Data
anticipated 2022+
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Primary endpoint(s)
|
Timeline
|
Status
|
NAVIGATOR
|
Severe
asthma
|
Placebo
or tezepelumab 210mg Q4W SC
|
Annual
asthma exacerbation rate
|
FPCD
Q1
2018
LPCD
Q3
2019
|
Primary
endpoint met
Breakthrough
Therapy Designation
(US)
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
COV001[84]
(UK)
Phase
I/II
|
Protection
against COVID-19 in participants aged 18-55
|
MenACWY
or C19VAZ
|
FPCD
Q2
2020
LPCD
Q2
2020
|
Initial
data readout
Recruitment completed
Regulatory approval (UK, EU)
|
COV00283
(UK)
Phase
II/III
|
Protection
against COVID-19 in participants aged 18-55, 55+
|
MenACWY
or C19VAZ
|
FPCD
Q2
2020
LPCD
Q4
2020
|
Initial
data readout
Recruitment completed
Regulatory approval (UK, EU)
|
COV003
(Brazil)
Phase
II/III
|
Protection
against COVID-19 in participants aged 18-55
|
MenACWY
or C19VAZ
|
FPCD
Q2
2020
LPCD
Q4
2020
|
Initial
data readout
Recruitment completed
Regulatory approval (UK, EU)
|
COV005ChAdOx1
nCoV-19 ZA[85]
(South
Africa)
Phase
I/II
|
Protection
against COVID-19 in participants aged 18-65
HIV+[86] subgroup
|
Placebo
or C19VAZ
|
FPCD
Q2
2020
LPCD
Q4
2020
First
data anticipated
H1
2021
|
Recruitment completed
|
D8110C00001
(US,
global)
Phase
III
|
Protection
against
COVID-19
in participants aged 18+
|
Placebo
or C19VAZ
|
FPCD
Q3
2020
First
data anticipated
H1
2021
|
Recruitment completed
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
PROVENT
|
Protection
against
COVID-19
(prophylaxis)
|
Placebo
or
AZD7442 300mg IM[87]
|
FPCD
Q4
2020
First
data anticipated
H2
2021
|
Recruitment
ongoing
|
STORM
CHASER
|
Protection
against
COVID-19
(post-exposure
prophylaxis)
|
Placebo
or
AZD7442 300mg IM
|
FPCD
Q4
2020
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
TACKLE
|
COVID-19
(outpatient treatment)
|
Placebo
or
AZD7442 600mg IM
|
FPCD
Q1
2021
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
ACTIV-2[88]
|
COVID-19
(outpatient treatment)
|
Placebo
or
AZD7442
|
FPCD
Q1
2021
|
Initiating
|
ACTIV-387
|
COVID-19
(inpatient
treatment)
|
Placebo
or
AZD7442
|
FPCD
Q1
2021
|
Recruitment
ongoing
|
Trial
|
Population
|
Design
|
Timeline
|
Status
|
Farxiga
|
||||
DARE-19[90]
Phase
III
|
COVID-19
|
Current
SoC
or
current SoC +
Farxiga
|
FPCD
Q2
2020
LPCD
Q1
2021
First
data anticipated
H1
2021
|
Recruitment
completed
|
TACTIC-E[91]
Phase
II
|
COVID-19
|
Current
SoC or current SoC + Farxiga + ambrisentan
|
FPCD
Q4
2020
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
Symbicort
|
||||
INHASCO[92]
Phase
IIIa
|
COVID-19
|
Current
SoC or SoC + Symbicort
|
FPCD
Q2
2020
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
Pulmicort
|
||||
TACTIC-COVID[93]
Phase
IIIa
|
COVID-19
|
Current
SoC or SoC + Pulmicort
|
FPCD
Q2
2020
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
MEDI3506 (IL33 monoclonal antibody)
|
||||
ACCORD[94]
Phase
II
|
COVID-19
|
Current
SoC or current SoC + MEDI3506
|
FPCD
Q2
2020
First
data anticipated
H1
2021
|
Recruitment
ongoing
|
For the year ended 31 December
|
2020
|
2019
|
$m
|
$m
|
|
Total Revenue
|
26,617
|
24,384
|
Product Sales
|
25,890
|
23,565
|
Collaboration Revenue
|
727
|
819
|
|
|
|
Cost of Sales
|
(5,299)
|
(4,921)
|
|
|
|
Gross Profit
|
21,318
|
19,463
|
|
|
|
Distribution costs
|
(399)
|
(339)
|
Research and development expense
|
(5,991)
|
(6,059)
|
Selling, general and administrative costs
|
(11,294)
|
(11,682)
|
Other operating income and expense
|
1,528
|
1,541
|
|
|
|
Operating Profit
|
5,162
|
2,924
|
Finance income
|
87
|
172
|
Finance expense
|
(1,306)
|
(1,432)
|
Share of after-tax losses in associates and joint
ventures
|
(27)
|
(116)
|
|
|
|
Profit Before Tax
|
3,916
|
1,548
|
Taxation
|
(772)
|
(321)
|
Profit for the period
|
3,144
|
1,227
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
(168)
|
(364)
|
Net gains/(losses) on equity investments measured at fair value
through other comprehensive income
|
938
|
(28)
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
(1)
|
(5)
|
Tax on items that will not be reclassified to profit or
loss
|
(81)
|
21
|
|
688
|
(376)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
443
|
40
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
573
|
(252)
|
Fair value movements on cash flow hedges
|
180
|
(101)
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
(254)
|
52
|
Fair value movements on derivatives designated in net investment
hedges
|
8
|
35
|
Gains/(costs) of hedging
|
9
|
(47)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
(39)
|
38
|
|
920
|
(235)
|
Other comprehensive income/(loss) for the period, net of
tax
|
1,608
|
(611)
|
Total comprehensive income for the period
|
4,752
|
616
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
3,196
|
1,335
|
Non-controlling interests
|
(52)
|
(108)
|
|
3,144
|
1,227
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
4,804
|
723
|
Non-controlling interests
|
(52)
|
(107)
|
|
4,752
|
616
|
Basic earnings per $0.25 Ordinary Share
|
$2.44
|
$1.03
|
Diluted earnings per $0.25 Ordinary Share
|
$2.44
|
$1.03
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,301
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,301
|
For the quarter ended 31 December
|
2020
|
2019
|
$m
|
$m
|
|
Total Revenue
|
7,410
|
6,664
|
Product Sales
|
7,011
|
6,250
|
Collaboration Revenue
|
399
|
414
|
|
|
|
Cost of Sales
|
(1,525)
|
(1,378)
|
|
|
|
Gross Profit
|
5,885
|
5,286
|
|
|
|
Distribution costs
|
(109)
|
(92)
|
Research and development expense
|
(1,719)
|
(2,091)
|
Selling, general and administrative costs
|
(3,210)
|
(3,026)
|
Other operating income and expense
|
640
|
500
|
|
|
|
Operating Profit
|
1,487
|
577
|
Finance income
|
7
|
39
|
Finance expense
|
(321)
|
(351)
|
Share of after-tax losses in associates and joint
ventures
|
(6)
|
(25)
|
|
|
|
Profit Before Tax
|
1,167
|
240
|
Taxation
|
(162)
|
37
|
Profit for the period
|
1,005
|
277
|
|
|
|
Other comprehensive income
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
Remeasurement of the defined benefit pension liability
|
23
|
(213)
|
Net losses on equity investments measured at fair value through
other comprehensive income
|
(36)
|
108
|
Fair value movements related to own credit risk on bonds designated
as fair value through profit or loss
|
-
|
(4)
|
Tax on items that will not be reclassified to profit or
loss
|
(11)
|
-
|
|
(24)
|
(109)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
Foreign exchange arising on consolidation
|
564
|
425
|
Foreign exchange arising on designated borrowings in net investment
hedges
|
428
|
239
|
Fair value movements on cash flow hedges
|
178
|
55
|
Fair value movements on cash flow hedges transferred to profit or
loss
|
(139)
|
(57)
|
Fair value movements on derivatives designated in net investment
hedges
|
(31)
|
-
|
Costs of hedging
|
(1)
|
(12)
|
Tax on items that may be reclassified subsequently to profit or
loss
|
(46)
|
(24)
|
|
953
|
626
|
Other comprehensive income for the period, net of tax
|
929
|
517
|
Total comprehensive income for the period
|
1,934
|
794
|
|
|
|
Profit attributable to:
|
|
|
Owners of the Parent
|
1,012
|
313
|
Non-controlling interests
|
(7)
|
(36)
|
|
1,005
|
277
|
Total comprehensive income attributable to:
|
|
|
Owners of the Parent
|
1,940
|
830
|
Non-controlling interests
|
(6)
|
(36)
|
|
1,934
|
794
|
Basic earnings per $0.25 Ordinary Share
|
$0.78
|
$0.24
|
Diluted earnings per $0.25 Ordinary Share
|
$0.78
|
$0.24
|
|
|
|
Weighted average number of Ordinary Shares in issue
(millions)
|
1,312
|
1,312
|
Diluted weighted average number of Ordinary Shares in issue
(millions)
|
1,313
|
1,312
|
|
At 31 Dec 2020
|
At 31 Dec 2019
|
$m
|
$m
|
|
Assets
|
|
|
Non-current assets
|
|
|
Property, plant and equipment
|
8,251
|
7,688
|
Right-of-use assets
|
666
|
647
|
Goodwill
|
11,845
|
11,668
|
Intangible assets
|
20,947
|
20,833
|
Investments in associates and joint ventures
|
39
|
58
|
Other investments
|
1,108
|
1,401
|
Derivative financial instruments
|
171
|
61
|
Other receivables
|
720
|
740
|
Deferred tax assets
|
3,438
|
2,718
|
|
|
|
|
47,185
|
45,814
|
|
|
|
Current assets
|
|
|
Inventories
|
4,024
|
3,193
|
Trade and other receivables
|
7,022
|
5,761
|
Other investments
|
160
|
849
|
Derivative financial instruments
|
142
|
36
|
Income tax receivable
|
364
|
285
|
Cash and cash equivalents
|
7,832
|
5,369
|
Assets held for sale
|
-
|
70
|
|
19,544
|
15,563
|
|
|
|
Total assets
|
66,729
|
61,377
|
|
|
|
Liabilities
|
|
|
Current liabilities
|
|
|
Interest-bearing loans and borrowings
|
(2,194)
|
(1,822)
|
Lease liabilities
|
(192)
|
(188)
|
Trade and other payables
|
(15,785)
|
(13,987)
|
Derivative financial instruments
|
(33)
|
(36)
|
Provisions
|
(976)
|
(723)
|
Income tax payable
|
(1,127)
|
(1,361)
|
|
(20,307)
|
(18,117)
|
Non-current liabilities
|
|
|
Interest-bearing loans and borrowings
|
(17,505)
|
(15,730)
|
Lease liabilities
|
(489)
|
(487)
|
Derivative financial instruments
|
(2)
|
(18)
|
Deferred tax liabilities
|
(2,918)
|
(2,490)
|
Retirement benefit obligations
|
(3,202)
|
(2,807)
|
Provisions
|
(584)
|
(841)
|
Other payables
|
(6,084)
|
(6,291)
|
|
(30,784)
|
(28,664)
|
Total liabilities
|
(51,091)
|
(46,781)
|
|
|
|
Net assets
|
15,638
|
14,596
|
|
|
|
Equity
|
|
|
Capital and reserves attributable to equity holders of the
Parent
|
|
|
Share
capital
|
328
|
328
|
Share
premium account
|
7,971
|
7,941
|
Other
reserves
|
2,024
|
2,046
|
Retained earnings
|
5,299
|
2,812
|
|
|
|
|
15,622
|
13,127
|
|
|
|
Non-controlling interests
|
16
|
1,469
|
Total equity
|
15,638
|
14,596
|
|
Share capital
|
Share premium account
|
Other reserves
|
Retained earnings
|
Total attributable to owners of the parent
|
Non-controlling interests
|
Total equity
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
At 1 Jan 2019
|
317
|
4,427
|
2,041
|
5,683
|
12,468
|
1,576
|
14,044
|
|
|
|
|
|
|
|
|
Adoption of new accounting standards
|
-
|
-
|
-
|
54
|
54
|
-
|
54
|
Profit for the period
|
-
|
-
|
-
|
1,335
|
1,335
|
(108)
|
1,227
|
Other comprehensive loss
|
-
|
-
|
-
|
(612)
|
(612)
|
1
|
(611)
|
Transfer to other reserves
|
-
|
-
|
5
|
(5)
|
-
|
-
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,579)
|
(3,579)
|
-
|
(3,579)
|
Issue of Ordinary Shares
|
11
|
3,514
|
-
|
-
|
3,525
|
-
|
3,525
|
Share-based payments charge for the period
|
-
|
-
|
-
|
259
|
259
|
-
|
259
|
Settlement of share plan awards
|
-
|
-
|
-
|
(323)
|
(323)
|
-
|
(323)
|
|
|
|
|
|
|
|
|
Net movement
|
11
|
3,514
|
5
|
(2,871)
|
659
|
(107)
|
552
|
|
|
|
|
|
|
|
|
At 31 Dec 2019
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
|
|
|
|
|
|
|
|
At 1 Jan 2020
|
328
|
7,941
|
2,046
|
2,812
|
13,127
|
1,469
|
14,596
|
|
|
|
|
|
|
|
|
Profit for the period
|
-
|
-
|
-
|
3,196
|
3,196
|
(52)
|
3,144
|
Other comprehensive income
|
-
|
-
|
-
|
1,608
|
1,608
|
-
|
1,608
|
Transfer to other reserves[96]
|
-
|
-
|
(22)
|
1,423
|
1,401
|
(1,401)
|
-
|
Transactions with owners:
|
|
|
|
|
|
|
|
Dividends
|
-
|
-
|
-
|
(3,668)
|
(3,668)
|
-
|
(3,668)
|
Issue of Ordinary Shares
|
-
|
30
|
-
|
-
|
30
|
-
|
30
|
Share-based payments charge for the period
|
-
|
-
|
-
|
277
|
277
|
-
|
277
|
Settlement of share plan awards
|
-
|
-
|
-
|
(349)
|
(349)
|
-
|
(349)
|
|
|
|
|
|
|
|
|
Net movement
|
-
|
30
|
(22)
|
2,487
|
2,495
|
(1,453)
|
1,042
|
|
|
|
|
|
|
|
|
At 31 Dec 2020
|
328
|
7,971
|
2,024
|
5,299
|
15,622
|
16
|
15,638
|
For the year ended 31 December
|
2020
|
2019
|
$m
|
$m
|
|
Cash flows from operating activities
|
|
|
Profit Before Tax
|
3,916
|
1,548
|
Finance income and expense
|
1,219
|
1,260
|
Share of after-tax losses of associates and joint
ventures
|
27
|
116
|
Depreciation, amortisation and impairment
|
3,149
|
3,762
|
Decrease/(increase) in working capital and short-term
provisions
|
361
|
(346)
|
Gains on disposal of intangible assets
|
(1,030)
|
(1,243)
|
Fair value movements on contingent consideration arising from
business combinations
|
(272)
|
(614)
|
Non-cash and other movements
|
(276)
|
378
|
|
|
|
Cash generated from operations
|
7,094
|
4,861
|
Interest paid
|
(733)
|
(774)
|
Tax paid
|
(1,562)
|
(1,118)
|
|
|
|
Net cash inflow from operating activities
|
4,799
|
2,969
|
|
|
|
Cash flows from investing activities
|
|
|
Payment of contingent consideration from business
combinations
|
(822)
|
(709)
|
Purchase of property, plant and equipment
|
(961)
|
(979)
|
Disposal of property, plant and equipment
|
106
|
37
|
Purchase of intangible assets
|
(1,645)
|
(1,481)
|
Disposal of intangible assets
|
951
|
2,076
|
Movement
in profit-participation liability
|
40
|
150
|
Purchase of non-current asset investments
|
(119)
|
(13)
|
Disposal of non-current asset investments
|
1,381
|
18
|
Movement in short-term investments, fixed deposits and other
investing instruments
|
745
|
194
|
Payments to associates and joint ventures
|
(8)
|
(74)
|
Interest received
|
47
|
124
|
|
|
|
Net cash outflow from investing activities
|
(285)
|
(657)
|
|
|
|
Net cash inflow before financing activities
|
4,514
|
2,312
|
|
|
|
Cash flows from financing activities
|
|
|
Proceeds from issue of share capital
|
30
|
3,525
|
Issue of loans
|
2,968
|
500
|
Repayment of loans
|
(1,609)
|
(1,500)
|
Dividends paid
|
(3,572)
|
(3,592)
|
Hedge contracts relating to dividend payments
|
(101)
|
4
|
Repayment of obligations under leases
|
(207)
|
(186)
|
Movement in short-term borrowings
|
288
|
(516)
|
|
|
|
Net cash outflow from financing activities
|
(2,203)
|
(1,765)
|
|
|
|
Net increase in cash and cash equivalents in the
period
|
2,311
|
547
|
Cash and cash equivalents at the beginning of the
period
|
5,223
|
4,671
|
Exchange rate effects
|
12
|
5
|
|
|
|
Cash and cash equivalents at the end of the period
|
7,546
|
5,223
|
|
|
|
Cash and cash equivalents consist of:
|
|
|
Cash and cash equivalents
|
7,832
|
5,369
|
Overdrafts
|
(286)
|
(146)
|
|
|
|
|
7,546
|
5,223
|
|
At
1 Jan 2020
|
Cash flow
|
Non-cash & other
|
Exchange movements
|
At
31 Dec 2020
|
$m
|
$m
|
$m
|
$m
|
$m
|
|
Non-current instalments of loans
|
(15,730)
|
(2,968)
|
1,394
|
(201)
|
(17,505)
|
Non-current instalments of leases
|
(487)
|
-
|
11
|
(13)
|
(489)
|
|
|
|
|
|
|
Total long-term debt
|
(16,217)
|
(2,968)
|
1,405
|
(214)
|
(17,994)
|
|
|
|
|
|
|
Current instalments of loans
|
(1,597)
|
1,609
|
(1,411)
|
(137)
|
(1,536)
|
Current instalments of leases
|
(188)
|
226
|
(225)
|
(5)
|
(192)
|
Bank collateral
|
(71)
|
(217)
|
-
|
-
|
(288)
|
Other short-term borrowings excluding overdrafts
|
(8)
|
(71)
|
-
|
(5)
|
(84)
|
Overdraft
|
(146)
|
(138)
|
-
|
(2)
|
(286)
|
|
|
|
|
|
|
Total current debt
|
(2,010)
|
1,409
|
(1,636)
|
(149)
|
(2,386)
|
|
|
|
|
|
|
Gross borrowings
|
(18,227)
|
(1,559)
|
(231)
|
(363)
|
(20,380)
|
|
|
|
|
|
|
Net derivative financial instruments
|
43
|
101
|
134
|
-
|
278
|
|
|
|
|
|
|
Net borrowings
|
(18,184)
|
(1,458)
|
(97)
|
(363)
|
(20,102)
|
|
|
|
|
|
|
Cash and cash equivalents
|
5,369
|
2,449
|
-
|
14
|
7,832
|
Other investments - current
|
849
|
(745)
|
61
|
(5)
|
160
|
Other investments - non-current
|
62
|
-
|
(62)
|
-
|
-
|
Cash and investments
|
6,280
|
1,704
|
(1)
|
9
|
7,992
|
|
|
|
|
|
|
Net Debt
|
(11,904)
|
246
|
(98)
|
(354)
|
(12,110)
|
|
2020
|
2019
|
||
Diabetes alliance
|
Other
|
Total
|
Total
|
|
$m
|
$m
|
$m
|
$m
|
|
At 1 January
|
3,300
|
839
|
4,139
|
5,106
|
Settlements
|
(546)
|
(276)
|
(822)
|
(709)
|
Revaluations
|
(51)
|
(221)
|
(272)
|
(614)
|
Discount unwind
|
229
|
49
|
278
|
356
|
|
|
|
|
|
At 31 December
|
2,932
|
391
|
3,323
|
4,139
|
7)
|
Table 45:
Product Sales year-on-year analysis - FY 2020[97]
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
4,328
|
36
|
36
|
1,208
|
59
|
63
|
1,566
|
24
|
748
|
58
|
56
|
806
|
18
|
16
|
Imfinzi
|
2,042
|
39
|
39
|
158
|
n/m
|
n/m
|
1,185
|
14
|
370
|
n/m
|
n/m
|
329
|
51
|
49
|
Lynparza
|
1,776
|
48
|
49
|
264
|
98
|
n/m
|
876
|
40
|
435
|
52
|
51
|
201
|
32
|
32
|
Calquence
|
522
|
n/m
|
n/m
|
6
|
n/m
|
n/m
|
511
|
n/m
|
2
|
n/m
|
n/m
|
3
|
n/m
|
n/m
|
Koselugo
|
38
|
n/m
|
n/m
|
-
|
-
|
-
|
38
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex*
|
888
|
9
|
13
|
561
|
14
|
20
|
5
|
(22)
|
140
|
4
|
4
|
182
|
1
|
1
|
Faslodex*
|
580
|
(35)
|
(34)
|
180
|
(9)
|
(4)
|
55
|
(83)
|
221
|
(3)
|
(3)
|
124
|
(10)
|
(11)
|
Iressa*
|
268
|
(37)
|
(36)
|
221
|
(23)
|
(22)
|
14
|
(21)
|
12
|
(82)
|
(82)
|
21
|
(57)
|
(57)
|
Arimidex*
|
185
|
(18)
|
(16)
|
147
|
(3)
|
1
|
-
|
-
|
3
|
(88)
|
(88)
|
35
|
(23)
|
(24)
|
Casodex*
|
172
|
(14)
|
(14)
|
133
|
4
|
6
|
-
|
-
|
3
|
(83)
|
(83)
|
36
|
(37)
|
(38)
|
Others
|
51
|
(47)
|
(46)
|
28
|
(1)
|
1
|
-
|
-
|
4
|
(41)
|
(40)
|
19
|
(69)
|
(69)
|
Total Oncology
|
10,850
|
25
|
26
|
2,906
|
31
|
36
|
4,250
|
23
|
1,938
|
36
|
35
|
1,756
|
11
|
10
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
1,959
|
27
|
30
|
686
|
46
|
55
|
569
|
6
|
507
|
36
|
35
|
197
|
21
|
21
|
Brilinta
|
1,593
|
1
|
2
|
461
|
-
|
4
|
732
|
3
|
342
|
(3)
|
(3)
|
58
|
-
|
2
|
Onglyza
|
470
|
(11)
|
(10)
|
201
|
14
|
18
|
166
|
(28)
|
58
|
(16)
|
(17)
|
45
|
(12)
|
(11)
|
Bydureon
|
448
|
(18)
|
(18)
|
4
|
(62)
|
(59)
|
382
|
(17)
|
53
|
(20)
|
(20)
|
9
|
(32)
|
(31)
|
Byetta
|
68
|
(37)
|
(36)
|
8
|
(35)
|
(23)
|
37
|
(45)
|
14
|
(24)
|
(24)
|
9
|
(18)
|
(17)
|
Other diabetes
|
47
|
(10)
|
(10)
|
7
|
n/m
|
n/m
|
25
|
(37)
|
13
|
38
|
38
|
2
|
26
|
28
|
Lokelma
|
76
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
57
|
n/m
|
4
|
n/m
|
n/m
|
10
|
n/m
|
n/m
|
Crestor*
|
1,180
|
(8)
|
(7)
|
748
|
(7)
|
(5)
|
92
|
(11)
|
129
|
(13)
|
(15)
|
211
|
(4)
|
(5)
|
Seloken/Toprol-XL*
|
821
|
8
|
12
|
782
|
14
|
18
|
13
|
(66)
|
16
|
(35)
|
(35)
|
10
|
(11)
|
(10)
|
Atacand*
|
243
|
10
|
15
|
175
|
9
|
17
|
10
|
(12)
|
35
|
17
|
17
|
23
|
15
|
15
|
Others
|
191
|
(30)
|
(30)
|
126
|
(35)
|
(34)
|
-
|
n/m
|
57
|
(5)
|
(4)
|
8
|
(60)
|
(61)
|
BioPharmaceuticals: total CVRM
|
7,096
|
3
|
5
|
3,203
|
8
|
12
|
2,083
|
(6)
|
1,228
|
7
|
6
|
582
|
2
|
2
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
2,721
|
9
|
10
|
567
|
4
|
9
|
1,022
|
23
|
694
|
2
|
2
|
438
|
(1)
|
-
|
Pulmicort
|
996
|
(32)
|
(32)
|
798
|
(33)
|
(33)
|
71
|
(35)
|
73
|
(10)
|
(10)
|
54
|
(37)
|
(37)
|
Fasenra
|
949
|
35
|
34
|
12
|
n/m
|
n/m
|
603
|
25
|
203
|
72
|
70
|
131
|
33
|
32
|
Daliresp/Daxas
|
217
|
1
|
1
|
4
|
(9)
|
(8)
|
190
|
3
|
22
|
(14)
|
(13)
|
1
|
(10)
|
(8)
|
Bevespi
|
48
|
16
|
15
|
1
|
n/m
|
n/m
|
44
|
7
|
3
|
n/m
|
n/m
|
-
|
-
|
-
|
Breztri
|
28
|
n/m
|
n/m
|
14
|
n/m
|
n/m
|
5
|
n/m
|
-
|
-
|
-
|
9
|
n/m
|
n/m
|
Others
|
398
|
(15)
|
(15)
|
203
|
(15)
|
(16)
|
6
|
(12)
|
176
|
(14)
|
(15)
|
13
|
(15)
|
(7)
|
BioPharmaceuticals: total Respiratory & Immunology
|
5,357
|
(1)
|
-
|
1,599
|
(20)
|
(18)
|
1,941
|
17
|
1,171
|
6
|
5
|
646
|
-
|
1
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium*
|
1,492
|
1
|
2
|
757
|
1
|
4
|
169
|
(22)
|
71
|
12
|
10
|
495
|
9
|
8
|
Synagis*
|
372
|
4
|
4
|
-
|
-
|
-
|
47
|
2
|
325
|
4
|
4
|
-
|
-
|
-
|
FluMist*
|
295
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
70
|
n/m
|
219
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
Losec/Prilosec*
|
183
|
(30)
|
(30)
|
152
|
(15)
|
(14)
|
6
|
(44)
|
20
|
(59)
|
(59)
|
5
|
(78)
|
(79)
|
Seroquel XR/IR*
|
117
|
(39)
|
(37)
|
55
|
11
|
14
|
17
|
(48)
|
29
|
(67)
|
(67)
|
16
|
(19)
|
(18)
|
Others
|
128
|
(33)
|
(34)
|
6
|
(51)
|
(44)
|
55
|
(50)
|
58
|
(7)
|
(8)
|
9
|
6
|
(5)
|
Total other medicines
|
2,587
|
(1)
|
-
|
971
|
(2)
|
1
|
364
|
(17)
|
722
|
8
|
7
|
530
|
5
|
3
|
Total Product Sales
|
25,890
|
10
|
11
|
8,679
|
6
|
10
|
8,638
|
12
|
5,059
|
16
|
15
|
3,514
|
6
|
6
|
8)
|
Table 46:
Product Sales year-on-year analysis - Q4 2020[98]
|
|
World
|
Emerging Markets
|
US
|
Europe
|
Established RoW
|
|||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
Actual
|
CER
|
Actual
|
CER
|
||||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
1,157
|
31
|
28
|
258
|
23
|
23
|
422
|
18
|
245
|
80
|
69
|
232
|
29
|
25
|
Imfinzi
|
555
|
31
|
29
|
45
|
n/m
|
n/m
|
300
|
6
|
115
|
78
|
68
|
95
|
44
|
41
|
Lynparza
|
496
|
42
|
40
|
69
|
n/m
|
n/m
|
245
|
27
|
124
|
58
|
49
|
58
|
29
|
27
|
Calquence
|
182
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
176
|
n/m
|
2
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
Koselugo
|
17
|
n/m
|
n/m
|
-
|
-
|
-
|
17
|
n/m
|
-
|
-
|
-
|
-
|
-
|
-
|
Zoladex*
|
216
|
11
|
13
|
134
|
20
|
27
|
(1)
|
n/m
|
36
|
2
|
(3)
|
47
|
-
|
(4)
|
Faslodex*
|
130
|
(21)
|
(22)
|
39
|
(27)
|
(22)
|
10
|
(40)
|
50
|
(17)
|
(22)
|
31
|
(12)
|
(14)
|
Iressa*
|
67
|
(16)
|
(19)
|
58
|
(2)
|
(6)
|
3
|
(7)
|
1
|
(88)
|
(89)
|
5
|
(41)
|
(43)
|
Arimidex*
|
36
|
(29)
|
(30)
|
26
|
(22)
|
(23)
|
-
|
-
|
1
|
(87)
|
(88)
|
9
|
(9)
|
(13)
|
Casodex*
|
39
|
(10)
|
(13)
|
29
|
3
|
(1)
|
-
|
-
|
1
|
(80)
|
(80)
|
9
|
(16)
|
(22)
|
Others
|
13
|
(53)
|
(52)
|
8
|
25
|
19
|
-
|
-
|
-
|
(86)
|
(87)
|
5
|
(74)
|
(74)
|
Total Oncology
|
2,908
|
28
|
26
|
668
|
22
|
24
|
1,172
|
29
|
575
|
45
|
37
|
493
|
17
|
14
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
586
|
40
|
40
|
198
|
50
|
57
|
184
|
31
|
144
|
45
|
36
|
60
|
27
|
24
|
Brilinta
|
363
|
(15)
|
(15)
|
69
|
(39)
|
(36)
|
195
|
(7)
|
85
|
(5)
|
(10)
|
14
|
(6)
|
(7)
|
Onglyza
|
105
|
(20)
|
(21)
|
47
|
3
|
4
|
32
|
(44)
|
15
|
(6)
|
(12)
|
11
|
(18)
|
(16)
|
Bydureon
|
122
|
(12)
|
(12)
|
1
|
(26)
|
(18)
|
105
|
(12)
|
14
|
(7)
|
(11)
|
2
|
(42)
|
(49)
|
Byetta
|
19
|
(31)
|
(30)
|
-
|
n/m
|
(85)
|
13
|
(18)
|
4
|
(16)
|
(21)
|
2
|
(15)
|
(18)
|
Other diabetes
|
12
|
(23)
|
(22)
|
2
|
n/m
|
n/m
|
6
|
(53)
|
4
|
45
|
38
|
-
|
(43)
|
6
|
Lokelma
|
28
|
n/m
|
n/m
|
1
|
n/m
|
n/m
|
20
|
n/m
|
2
|
n/m
|
n/m
|
5
|
n/m
|
n/m
|
Crestor*
|
298
|
1
|
(1)
|
189
|
2
|
1
|
21
|
33
|
34
|
(7)
|
(13)
|
54
|
(8)
|
(11)
|
Seloken/Toprol-XL*
|
200
|
6
|
7
|
190
|
10
|
11
|
3
|
(52)
|
4
|
(32)
|
(32)
|
3
|
(7)
|
(18)
|
Atacand*
|
63
|
5
|
9
|
42
|
(2)
|
4
|
3
|
(16)
|
13
|
63
|
63
|
5
|
(7)
|
(15)
|
Others
|
46
|
(38)
|
(40)
|
33
|
(40)
|
(43)
|
-
|
n/m
|
12
|
(14)
|
(12)
|
1
|
(73)
|
(79)
|
BioPharmaceuticals: total CVRM
|
1,842
|
3
|
3
|
772
|
3
|
5
|
582
|
(1)
|
331
|
13
|
7
|
157
|
3
|
-
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
680
|
(5)
|
(5)
|
145
|
(1)
|
3
|
267
|
9
|
173
|
1
|
(4)
|
95
|
(37)
|
(38)
|
Pulmicort
|
368
|
(11)
|
(14)
|
319
|
(8)
|
(11)
|
18
|
(14)
|
18
|
(17)
|
(20)
|
13
|
(49)
|
(50)
|
Fasenra
|
283
|
38
|
35
|
2
|
24
|
37
|
180
|
30
|
63
|
72
|
61
|
38
|
31
|
27
|
Daliresp/Daxas
|
54
|
(6)
|
(7)
|
1
|
-
|
(6)
|
49
|
(3)
|
4
|
(35)
|
(37)
|
-
|
-
|
-
|
Bevespi
|
12
|
8
|
4
|
-
|
-
|
-
|
11
|
(5)
|
1
|
n/m
|
n/m
|
-
|
-
|
-
|
Breztri
|
6
|
n/m
|
n/m
|
(1)
|
n/m
|
n/m
|
2
|
n/m
|
-
|
-
|
-
|
5
|
n/m
|
n/m
|
Others
|
125
|
(8)
|
(12)
|
81
|
10
|
4
|
(2)
|
n/m
|
44
|
(19)
|
(24)
|
2
|
(48)
|
(20)
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,528
|
(1)
|
(2)
|
547
|
(4)
|
(5)
|
525
|
12
|
303
|
5
|
(1)
|
153
|
(27)
|
(28)
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium*
|
377
|
7
|
6
|
193
|
11
|
11
|
42
|
(2)
|
12
|
(18)
|
(25)
|
130
|
6
|
3
|
Synagis*
|
78
|
24
|
24
|
-
|
-
|
-
|
-
|
n/m
|
78
|
46
|
47
|
-
|
-
|
-
|
FluMist*
|
179
|
92
|
85
|
1
|
n/m
|
n/m
|
5
|
n/m
|
170
|
83
|
76
|
3
|
n/m
|
n/m
|
Losec/Prilosec*
|
39
|
(15)
|
(18)
|
33
|
(2)
|
(6)
|
2
|
(26)
|
4
|
(16)
|
(12)
|
-
|
(96)
|
(95)
|
Seroquel XR/IR*
|
19
|
(53)
|
(49)
|
15
|
68
|
77
|
(5)
|
n/m
|
7
|
(65)
|
(63)
|
2
|
(58)
|
(55)
|
Others
|
41
|
(30)
|
(31)
|
-
|
n/m
|
(90)
|
17
|
(42)
|
20
|
15
|
9
|
4
|
12
|
(17)
|
Total other medicines
|
733
|
12
|
10
|
242
|
8
|
8
|
61
|
(33)
|
291
|
43
|
39
|
139
|
3
|
-
|
Total Product Sales
|
7,011
|
12
|
11
|
2,229
|
7
|
7
|
2,340
|
14
|
1,500
|
27
|
21
|
942
|
2
|
-
|
9)
|
Table 47:
Product Sales quarterly sequential analysis - FY 2020[99]
|
|
Q1 2020
|
Q2 2020
|
Q3 2020
|
Q4 2020
|
||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
982
|
11
|
11
|
1,034
|
5
|
7
|
1,155
|
12
|
9
|
1,157
|
-
|
(1)
|
Imfinzi
|
462
|
9
|
9
|
492
|
6
|
8
|
533
|
8
|
6
|
555
|
4
|
3
|
Lynparza
|
397
|
13
|
13
|
419
|
5
|
7
|
464
|
11
|
8
|
496
|
7
|
6
|
Calquence
|
88
|
58
|
58
|
107
|
21
|
23
|
145
|
36
|
35
|
182
|
25
|
25
|
Koselugo
|
-
|
-
|
-
|
7
|
n/m
|
n/m
|
13
|
75
|
75
|
17
|
34
|
34
|
Zoladex*
|
225
|
15
|
15
|
217
|
(3)
|
-
|
230
|
6
|
3
|
216
|
(6)
|
(7)
|
Faslodex*
|
166
|
-
|
-
|
146
|
(12)
|
(9)
|
138
|
(5)
|
(8)
|
130
|
(6)
|
(7)
|
Iressa*
|
77
|
(3)
|
(4)
|
70
|
(9)
|
(7)
|
54
|
(23)
|
(24)
|
67
|
24
|
19
|
Arimidex*
|
50
|
(1)
|
(2)
|
58
|
17
|
16
|
42
|
(28)
|
(27)
|
36
|
(14)
|
(16)
|
Casodex*
|
42
|
(2)
|
(3)
|
47
|
14
|
12
|
44
|
(7)
|
(8)
|
39
|
(11)
|
(14)
|
Others
|
13
|
(52)
|
(52)
|
12
|
(11)
|
(1)
|
13
|
4
|
3
|
13
|
2
|
2
|
Total Oncology
|
2,502
|
10
|
10
|
2,609
|
4
|
6
|
2,831
|
8
|
6
|
2,908
|
3
|
2
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
405
|
(3)
|
(3)
|
443
|
9
|
13
|
525
|
19
|
16
|
586
|
11
|
10
|
Brilinta
|
408
|
(5)
|
(5)
|
437
|
7
|
9
|
385
|
(12)
|
(13)
|
363
|
(6)
|
(6)
|
Onglyza
|
141
|
8
|
8
|
115
|
(19)
|
(17)
|
110
|
(6)
|
(6)
|
105
|
(4)
|
(5)
|
Bydureon
|
100
|
(28)
|
(28)
|
116
|
16
|
17
|
109
|
(5)
|
(7)
|
122
|
12
|
11
|
Byetta
|
20
|
(24)
|
(24)
|
15
|
(28)
|
(28)
|
15
|
1
|
4
|
19
|
26
|
24
|
Other diabetes
|
13
|
(22)
|
(22)
|
10
|
(21)
|
(19)
|
11
|
9
|
6
|
12
|
11
|
15
|
Lokelma
|
11
|
42
|
42
|
17
|
56
|
58
|
21
|
22
|
26
|
28
|
37
|
28
|
Crestor*
|
301
|
2
|
1
|
281
|
(7)
|
(4)
|
300
|
7
|
5
|
298
|
(1)
|
(4)
|
Seloken/Toprol-XL*
|
177
|
(6)
|
(6)
|
218
|
23
|
27
|
225
|
4
|
3
|
200
|
(11)
|
(13)
|
Atacand*
|
66
|
11
|
12
|
59
|
(11)
|
(5)
|
54
|
(9)
|
(12)
|
63
|
16
|
14
|
Others
|
59
|
(21)
|
(22)
|
48
|
(18)
|
(16)
|
39
|
(19)
|
(22)
|
46
|
18
|
17
|
BioPharmaceuticals: total CVRM
|
1,701
|
(5)
|
(5)
|
1,759
|
3
|
6
|
1,794
|
2
|
-
|
1,842
|
3
|
1
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
790
|
11
|
11
|
653
|
(17)
|
(15)
|
599
|
(8)
|
(11)
|
680
|
13
|
13
|
Pulmicort
|
380
|
(8)
|
(9)
|
97
|
(74)
|
(73)
|
151
|
56
|
49
|
368
|
n/m
|
n/m
|
Fasenra
|
199
|
(3)
|
(3)
|
227
|
14
|
15
|
240
|
5
|
4
|
283
|
18
|
17
|
Daliresp/Daxas
|
53
|
(8)
|
(8)
|
53
|
(1)
|
(3)
|
57
|
8
|
11
|
54
|
(4)
|
(6)
|
Bevespi
|
12
|
9
|
9
|
10
|
(19)
|
(21)
|
14
|
47
|
46
|
12
|
(16)
|
(17)
|
Breztri
|
4
|
n/m
|
n/m
|
7
|
58
|
64
|
10
|
45
|
48
|
6
|
(39)
|
(38)
|
Others
|
113
|
(16)
|
(17)
|
70
|
(38)
|
(36)
|
90
|
27
|
22
|
125
|
39
|
35
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,551
|
1
|
1
|
1,117
|
(28)
|
(26)
|
1,161
|
4
|
1
|
1,528
|
32
|
29
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium*
|
338
|
(4)
|
(4)
|
377
|
12
|
14
|
401
|
6
|
4
|
377
|
(6)
|
(7)
|
Synagis*
|
85
|
35
|
35
|
90
|
6
|
7
|
118
|
31
|
29
|
78
|
(34)
|
(33)
|
FluMist*
|
-
|
n/m
|
n/m
|
-
|
n/m
|
n/m
|
116
|
n/m
|
n/m
|
179
|
55
|
50
|
Losec/Prilosec*
|
54
|
18
|
17
|
45
|
(15)
|
(15)
|
45
|
-
|
-
|
39
|
(15)
|
(18)
|
Seroquel XR/IR*
|
36
|
(12)
|
(12)
|
27
|
(26)
|
(23)
|
35
|
32
|
29
|
19
|
(45)
|
(42)
|
Others
|
44
|
(71)
|
(70)
|
24
|
(46)
|
(42)
|
19
|
(17)
|
(19)
|
41
|
n/m
|
n/m
|
Total other medicines
|
557
|
(15)
|
(15)
|
563
|
1
|
4
|
734
|
30
|
27
|
733
|
-
|
(2)
|
Total Product Sales
|
6,311
|
1
|
1
|
6,048
|
(4)
|
(2)
|
6,520
|
8
|
6
|
7,011
|
8
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10)
|
Table 48: Product Sales quarterly sequential analysis - FY
2019[100]
|
|
Q1 2019
|
Q2 2019
|
Q3 2019
|
Q4 2019
|
||||||||
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
$m
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
630
|
6
|
6
|
784
|
24
|
25
|
891
|
14
|
13
|
884
|
(1)
|
-
|
Imfinzi
|
295
|
13
|
13
|
338
|
15
|
15
|
412
|
22
|
22
|
424
|
3
|
4
|
Lynparza
|
237
|
13
|
13
|
283
|
19
|
20
|
327
|
16
|
15
|
351
|
7
|
8
|
Calquence
|
29
|
21
|
23
|
35
|
21
|
19
|
44
|
27
|
27
|
56
|
25
|
25
|
Faslodex*
|
254
|
(6)
|
(6)
|
267
|
5
|
6
|
205
|
(23)
|
(23)
|
166
|
(20)
|
(19)
|
Zoladex*
|
194
|
7
|
6
|
197
|
2
|
1
|
226
|
15
|
16
|
196
|
(14)
|
(12)
|
Iressa*
|
134
|
20
|
18
|
118
|
(12)
|
(11)
|
91
|
(23)
|
(22)
|
80
|
(13)
|
(12)
|
Arimidex*
|
51
|
11
|
10
|
60
|
18
|
17
|
63
|
5
|
5
|
51
|
(20)
|
(18)
|
Casodex*
|
48
|
4
|
3
|
57
|
19
|
18
|
52
|
(8)
|
(6)
|
43
|
(18)
|
(17)
|
Others
|
20
|
(13)
|
(14)
|
28
|
40
|
29
|
20
|
(27)
|
(22)
|
26
|
30
|
26
|
Total Oncology
|
1,892
|
7
|
6
|
2,167
|
15
|
15
|
2,334
|
8
|
8
|
2,274
|
(3)
|
(2)
|
BioPharmaceuticals: CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
349
|
(12)
|
(12)
|
377
|
8
|
9
|
398
|
5
|
5
|
419
|
5
|
6
|
Brilinta
|
348
|
(7)
|
(8)
|
389
|
12
|
12
|
416
|
7
|
8
|
428
|
3
|
3
|
Onglyza
|
153
|
3
|
3
|
116
|
(24)
|
(24)
|
127
|
9
|
11
|
131
|
3
|
4
|
Bydureon
|
142
|
3
|
3
|
141
|
(1)
|
-
|
127
|
(10)
|
(10)
|
139
|
9
|
10
|
Byetta
|
30
|
(6)
|
(5)
|
25
|
(17)
|
(16)
|
28
|
10
|
13
|
27
|
(2)
|
(4)
|
Other diabetes
|
11
|
(8)
|
(17)
|
11
|
-
|
8
|
14
|
26
|
22
|
16
|
17
|
17
|
Lokelma*
|
-
|
n/m
|
n/m
|
2
|
n/m
|
n/m
|
4
|
n/m
|
n/m
|
8
|
87
|
74
|
Crestor*
|
335
|
(5)
|
(6)
|
310
|
(7)
|
(7)
|
337
|
9
|
9
|
296
|
(12)
|
(11)
|
Seloken/Toprol-XL*
|
225
|
41
|
38
|
168
|
(25)
|
(25)
|
177
|
6
|
8
|
190
|
7
|
8
|
Atacand*
|
50
|
(14)
|
(15)
|
56
|
12
|
14
|
55
|
(1)
|
(1)
|
60
|
8
|
9
|
Others
|
71
|
(3)
|
(5)
|
63
|
(11)
|
(8)
|
65
|
4
|
2
|
72
|
13
|
16
|
BioPharmaceuticals: total CVRM
|
1,714
|
(2)
|
(3)
|
1,658
|
(3)
|
(3)
|
1,749
|
5
|
6
|
1,785
|
2
|
3
|
BioPharmaceuticals: Respiratory & Immunology
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
585
|
(8)
|
(8)
|
585
|
-
|
1
|
613
|
5
|
4
|
712
|
16
|
17
|
Pulmicort
|
383
|
(2)
|
(2)
|
333
|
(13)
|
(13)
|
337
|
1
|
3
|
413
|
22
|
23
|
Fasenra
|
129
|
3
|
4
|
167
|
29
|
30
|
202
|
21
|
21
|
206
|
2
|
2
|
Daliresp/Daxas
|
48
|
(11)
|
(12)
|
56
|
17
|
18
|
53
|
(6)
|
(7)
|
58
|
10
|
10
|
Bevespi
|
10
|
-
|
(5)
|
10
|
-
|
2
|
10
|
4
|
8
|
12
|
8
|
5
|
Breztri
|
-
|
-
|
-
|
-
|
-
|
-
|
1
|
-
|
-
|
1
|
(74)
|
(73)
|
Others
|
128
|
(14)
|
(12)
|
101
|
(21)
|
(23)
|
102
|
1
|
(1)
|
135
|
33
|
38
|
BioPharmaceuticals: total Respiratory & Immunology
|
1,283
|
(6)
|
(6)
|
1,252
|
(2)
|
(2)
|
1,319
|
5
|
6
|
1,537
|
17
|
17
|
Other medicines
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium*
|
363
|
(7)
|
(8)
|
393
|
8
|
8
|
374
|
(5)
|
(4)
|
353
|
(6)
|
(6)
|
Synagis*
|
53
|
(79)
|
(79)
|
96
|
81
|
81
|
146
|
52
|
53
|
63
|
(57)
|
(57)
|
Losec/Prilosec*
|
76
|
27
|
26
|
68
|
(11)
|
(10)
|
73
|
8
|
9
|
46
|
(38)
|
(38)
|
Seroquel XR/IR*
|
37
|
(34)
|
(33)
|
32
|
(14)
|
(10)
|
82
|
n/m
|
n/m
|
40
|
(50)
|
(49)
|
Others
|
47
|
(65)
|
(64)
|
52
|
11
|
11
|
56
|
8
|
-
|
151
|
n/m
|
n/m
|
Total other medicines
|
576
|
(35)
|
(36)
|
641
|
11
|
12
|
731
|
14
|
14
|
653
|
(11)
|
(10)
|
Total Product Sales
|
5,465
|
(5)
|
(6)
|
5,718
|
5
|
5
|
6,132
|
7
|
8
|
6,250
|
2
|
3
|
|
|
FY 2020
|
FY 2019
|
FY 2018
|
$m
|
$m
|
$m
|
||
Initial Collaboration Revenue
|
Crestor (Spain)
|
-
|
-
|
61
|
Ongoing Collaboration Revenue
|
Lynparza: regulatory
milestones
|
160
|
60
|
140
|
Lynparza: sales
milestones
|
300
|
450
|
250
|
|
Lynparza/Koselugo: option payments
|
-
|
100
|
400
|
|
Crestor (Spain)
|
-
|
39
|
-
|
|
Enhertu: share of gross
profits
|
94
|
-
|
-
|
|
Roxadustat: share of gross profits
|
30
|
-
|
-
|
|
Royalty income
|
62
|
62
|
49
|
|
|
Other Collaboration Revenue
|
81
|
108
|
141
|
Total
|
727
|
819
|
1,041
|
|
FY 2020
|
FY 2019
|
FY 2018
|
$m
|
$m
|
$m
|
|
Hypertension medicines (ex-US, India and Japan)
|
350
|
-
|
-
|
Monetisation of an asset
previously licensed
|
120
|
-
|
-
|
Brazikumab licence termination funding
|
107
|
-
|
-
|
Inderal, Tenormin, Seloken and Omepral (Japan)
|
51
|
-
|
-
|
Synagis (US)
|
-
|
515
|
-
|
Losec (ex-China, Japan, US
and Mexico)
|
-
|
243
|
-
|
Seroquel and Seroquel XR (US, Canada, Europe and
Russia)
|
-
|
213
|
-
|
Arimidex and Casodex (various countries)
|
-
|
181
|
-
|
Nexium (Europe)
and Vimovo (ex-US)
|
54
|
-
|
728
|
Seroquel
|
-
|
-
|
527
|
Legal settlement
|
-
|
-
|
346
|
Atacand
|
400
|
-
|
210
|
Anaesthetics
|
-
|
-
|
172
|
Alvesco, Omnaris and Zetonna
|
-
|
-
|
139
|
Other
|
446
|
389
|
405
|
|
|
|
|
Total
|
1,528
|
1,541
|
2,527
|
Announcement of
first quarter results
|
30
April 2021
|
|
Announcement of
half year and second quarter results
|
29 July
2021
|
|
Announcement of
year to date and third quarter results
|
12
November 2021
|
|
|
||
Dividends are
normally be paid as follows:
|
||
First
interim:
|
announced
with the half-year and second-quarter results and paid in
September
|
|
Second
interim:
|
announced
with full-year and fourth-quarter results and paid in
March
|
|
|
|
|
|
|
|
|
Registered office
|
Registrar and transfer office
|
Swedish Central Securities Depository
|
US depositary
Deutsche Bank Trust Company Americas
|
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge
CB2 0AA
|
Equiniti Limited
Aspect House
Spencer Road
Lancing
West Sussex
BN99 6DA
|
Euroclear Sweden AB PO Box 191
SE-101 23 Stockholm
|
American Stock Transfer
6201 15th Avenue
Brooklyn
NY 11219
|
United Kingdom
|
United Kingdom
|
Sweden
|
United States
|
|
|
|
|
+44 (0) 20 3749 5000
|
0800 389 1580
|
+46 (0) 8 402 9000
|
+1 (888) 697 8018
|
|
+44 (0) 121 415 7033
|
|
+1 (718) 921 8137
|
|
|
|
db@astfinancial.com
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|